Literature DB >> 9728565

Lymph of patients with a systemic inflammatory response syndrome inhibits lipopolysaccharide-induced cytokine production.

L C Lemaire1, J J van Lanschot, T van der Poll, W A Buurman, S J van Deventer, D J Gouma.   

Abstract

In patients with systemic inflammatory response syndrome (SIRS), tolerance of peripheral blood mononuclear cells to a second challenge with lipopolysaccharide (LPS) has been described. Thoracic duct lymph transports LPS and represents the extravascular, interstitial fluid compartment of the body. The aim of this study was to determine the capacity of lymph to influence LPS-induced cytokine production in vitro. Thoracic duct lymph was obtained from patients with SIRS and without SIRS (controls). The effect of lymph and simultaneously collected plasma on LPS-induced cytokine production by normal peripheral blood mononuclear cells was assessed. Both lymph and plasma of patients with SIRS reduced LPS-induced tumor necrosis factor-alpha and interleukin-6 production (P < .01); lymph of controls also inhibited cytokine production (P < .01), although to a lesser extent. This study suggests that LPS tolerance may occur both in the intra- and extravascular compartments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728565     DOI: 10.1086/515348

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

Review 1.  Endotoxemia-menace, marker, or mistake?

Authors:  Robert S Munford
Journal:  J Leukoc Biol       Date:  2016-07-14       Impact factor: 4.962

2.  The transport and inactivation kinetics of bacterial lipopolysaccharide influence its immunological potency in vivo.

Authors:  Mingfang Lu; Robert S Munford
Journal:  J Immunol       Date:  2011-08-17       Impact factor: 5.422

Review 3.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.